期刊文献+

卵巢癌组织中HE4表达及与其临床病理因素的关系 被引量:15

HE4 Expression in Epithelial Ovarian Cancer Tissues and its Relationship with Clinicopathological Features
下载PDF
导出
摘要 目的探讨人附睾蛋白4(HE4)在卵巢上皮性癌组织中的表达及其与卵巢癌临床病理因素的关系。方法采用免疫组化法,检测不同卵巢组织中HE4蛋白表达水平,其中47例卵巢上皮性癌组织(以下简称卵巢癌组织)、20例正常卵巢组织、20例良性卵巢上皮性肿瘤组织。结果正常卵巢组织、上皮性良性卵巢肿瘤组织及卵巢癌组织中HE4阳性表达率分别为0(0/20),10.0%(2/20)和74.5%(35/47),卵巢癌组织中HE4阳性表达率分别高于正常卵巢组织和卵巢良性肿瘤组织,差异均有统计学意义(P<0.01,P<0.01)。正常卵巢组织与卵巢良性肿瘤组织HE4阳性表达率比较,差异无统计学意义(P>0.05)。卵巢癌晚期组(Ⅲ/Ⅳ期)HE4阳性率[89.5%(17/19)]较早期组(Ⅰ/Ⅱ期)[57.1%(16/28)]明显增高(P<0.05);中、低分化组其阳性率[92.6%(25/27)]较高分化组[65.0%(13/20)]明显增高(P<0.05);淋巴结转移组其阳性率[72.4%(21/29)]较无淋巴结转移组[38.9%(7/18)]明显增高(P<0.05)。HE4表达与卵巢癌患者年龄无关(P>0.05)。结论 HE4表达与卵巢癌临床分期、细胞分化及淋巴结转移有关,HE4可作为预测卵巢癌侵袭、转移及预后的指标。 Objective To explore the human epididymis protein 4(HE4) expression in epithelial ovarian cancer tissues and its relationship with clinicopathologic features.Methods Immunohistochemistry was used to detect the expression of HE4 protein in tissues,among this series,47 cases were epithelial ovarian cancer organization(hereinafter referred to as ovarian cancer tissue),20 cases were normal ovarian and 20 cases were benign ovarian tumor.The positive cell of staining section was measured by computer image processing software.Results In normal ovarian tissue,benign ovarian tumors and ovarian cancer tissue,positive expression rate of HE4 protein was respectively 0(0/20),10.0%(2/20),74.5%(35/47).The positive expression rate in ovarian carcinoma group was significantly higher than that in the normal ovarian and benign ovarian tumor groups(P0.01,P0.01).There was no significant statistical difference of positive expression rate of HE4 protein in normal ovarian tissue and benign ovarian tumor(P0.05).The HE4 protein positive expression rate was higher in ovarian cancer patients with the advanced stages(stage Ⅲ/Ⅳ,89.5%)compared with the early stages(stage Ⅰ/Ⅱ,57.1%)(P0.05);In the cell,the positive rate of the moderately and poorly differentiated groups(92.6%,25/27) was higher than well differentiation group(65.0%,13/20),(P0.05);The positive expression rate of HE4 protein in ovarian cancer with lymph node metastasis(72.4%,21/29) was higher than that without lymph node metastasis(38.9%,7/18),(P0.05).The expression of HE4 in patients with ovarian cancer has no correlation with age(P0.05).Conclusion HE4 expression level in tissue of ovarian cancer is closely related with clinical stages,cell grades and lymph node metastasis.HE4 can be used as an index,which predicting invasion,metastasis and prognosis of ovarian cancer.
出处 《实用癌症杂志》 2012年第6期578-582,共5页 The Practical Journal of Cancer
关键词 人附睾蛋白4 上皮性卵巢癌 免疫组织化学 Human epididymis protein 4 Epithelial ovarian cancer Immunohistochemistry.
  • 相关文献

参考文献7

二级参考文献32

共引文献143

同被引文献127

  • 1赵莹珺,杨剑峰,朱景德.人卵巢癌相关候选基因HE4(WFDC2)的转录调控主要由Sp1与位于-71和-48的Egr-1位点结合所介导[J].肿瘤,2004,24(6):517-525. 被引量:15
  • 2李红霞.卵巢癌规范化治疗的几个问题[J].现代医学,2005,33(1):1-3. 被引量:3
  • 3杨蓉,冯捷,房祥忠,白符,成夜霞,刘晨,朱炜,李林.浆液性卵巢癌预后评分模型的建立和预后相关基因的筛选[J].中国妇产科临床杂志,2007,8(4):277-281. 被引量:5
  • 4Schildkraut JM, Thompson WD. Familial ovarian cancer: a population- based case control study[J]. Am J Epidemiol, 1988,128 (3):456.
  • 5Watson P, Lynch HT. Hereditary ovarian cancer ( A 1. Sharp, Mason, e- ds. Ovarian cancer, biology, diagnosis and management [ M ]. London : Chapman and Hall Medical, 1992:9 - 24.
  • 6Chen S, Iversen ES, Friebel T, et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample [ J ]. Clin Oncol, 2006,24(6) :863.
  • 7Lynch HT, Lynch J F, Conway T A. Hereditary ovarian cancer In ovari- an cancer( RubinSC, Sutton GP, eds) [ M ]. NewYork : McGraw-Hill, 1993 : 189 ~ 217.
  • 8Ren P, Chen FF, Liu HY, et al. High serum levels of follistatin in patients with ovarian cancer[J]. J Int Med Res,2012,40(3) :877-886.
  • 9Kondalsamy CS, Haekethal A, Bowtell D,et al. Differ- entiating stage 1 epithelial ovarian cancer from benign o- varian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age[J]. Gynecol Oncol,2013,129(3) : 467-71.
  • 10You B, Colomban O, Heywood M,et al. The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: Data from CA- LYPSO trial (a GINECO-GCIG study)[J]. Gynecol Oncol, 2013,130(2) : 289-294.

引证文献15

二级引证文献86

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部